Volume 69, Issue 3, Pages (March 2016)

Slides:



Advertisements
Similar presentations
Volume 61, Issue 5, Pages (May 2012)
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 68, Issue 2, Pages (August 2015)
Volume 50, Issue 1, Pages (July 2006)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 44, Issue 6, Pages (December 2003)
Testosterone Therapy in Men With Prostate Cancer
Volume 58, Issue 5, Pages (November 2010)
Prostate Cancer: Highlights from 2006
Volume 60, Issue 1, Pages (July 2011)
Volume 67, Issue 3, Pages (March 2015)
Volume 53, Issue 5, Pages (May 2008)
Volume 65, Issue 1, Pages 7-16 (January 2014)
Volume 51, Issue 4, Pages (April 2007)
Volume 199, Issue 4, Pages e131-e132 (April 2018)
Volume 73, Issue 1, Pages (January 2018)
Volume 60, Issue 6, Pages (December 2011)
Volume 70, Issue 2, Pages (August 2016)
Volume 199, Issue 6, Pages (June 2018)
Volume 71, Issue 5, Pages (May 2017)
Volume 73, Issue 5, Pages (May 2018)
Prostate Cancer Epidemic in Sight?
Volume 63, Issue 1, Pages (January 2013)
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer  Sam Ladjevardi, Gabriel Sandblom,
Volume 54, Issue 4, Pages (October 2008)
Volume 68, Issue 5, Pages (November 2015)
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 68, Issue 3, Pages (September 2015)
Volume 67, Issue 3, Pages (March 2015)
Volume 64, Issue 5, Pages (November 2013)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Rodolfo Montironi, Ming Zhou, Cristina Magi-Galluzzi, Jonathan I
Volume 67, Issue 6, Pages (June 2015)
Volume 71, Issue 6, Pages (June 2017)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Volume 54, Issue 2, Pages (August 2008)
Volume 53, Issue 4, Pages (April 2008)
Volume 64, Issue 6, Pages (December 2013)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 59, Issue 3, Pages e7-e8 (March 2011)
Volume 61, Issue 5, Pages (May 2012)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 63, Issue 3, Pages (March 2013)
Volume 62, Issue 4, Pages (October 2012)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 71, Issue 1, Pages (January 2017)
Volume 68, Issue 6, Pages e134-e135 (December 2015)
Volume 65, Issue 4, Pages (April 2014)
Volume 65, Issue 1, Pages 7-16 (January 2014)
Volume 62, Issue 3, Pages (September 2012)
Volume 70, Issue 2, Pages (August 2016)
Volume 50, Issue 5, Pages (November 2006)
Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Volume 71, Issue 5, Pages (May 2017)
Testicular Cancer Variations in Time and Space in Europe
Volume 74, Issue 4, Pages (October 2018)
Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg 
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Volume 53, Issue 5, Pages (May 2008)
The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review  Fritz Schröder,
Volume 68, Issue 2, Pages (August 2015)
Volume 74, Issue 6, Pages (December 2018)
Volume 54, Issue 3, Pages (September 2008)
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 69, Issue 3, Pages 428-435 (March 2016) A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score  Jonathan I. Epstein, Michael J. Zelefsky, Daniel D. Sjoberg, Joel B. Nelson, Lars Egevad, Cristina Magi-Galluzzi, Andrew J. Vickers, Anil V. Parwani, Victor E. Reuter, Samson W. Fine, James A. Eastham, Peter Wiklund, Misop Han, Chandana A. Reddy, Jay P. Ciezki, Tommy Nyberg, Eric A. Klein  European Urology  Volume 69, Issue 3, Pages 428-435 (March 2016) DOI: 10.1016/j.eururo.2015.06.046 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Recurrence-free progression following radical prostatectomy stratified by prostatectomy grade. Green line: Gleason score ≤6, grade group 1. Orange line: Gleason score 3+4, grade group 2. Dark blue line: Gleason score 4+3, grade group 3. Red line: Gleason score 8, grade group 4. Purple line: Gleason score ≥9, grade group 5. RFP = recurrence-free progression. European Urology 2016 69, 428-435DOI: (10.1016/j.eururo.2015.06.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Recurrence-free progression following radical prostatectomy stratified by pre-prostatectomy biopsy grade. Green line: Gleason score ≤6, grade group 1. Orange line: Gleason score 3+4, grade group 2. Dark blue line: Gleason score 4+3, grade group 3. Red line: Gleason score 8, grade group 4. Purple line: Gleason score ≥9, grade group 5. RFP=recurrence-free progression. European Urology 2016 69, 428-435DOI: (10.1016/j.eururo.2015.06.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 Recurrence-free progression following radiation stratified by pre–radiation therapy biopsy grade (entire cohort). Green line: Gleason score ≤6, grade group 1. Orange line: Gleason score 3+4, grade group 2. Dark blue line: Gleason score 4+3, grade group 3. Red line: Gleason score 8, grade group 4. Purple line: Gleason score ≥9, grade group 5. RFP=recurrence-free progression. European Urology 2016 69, 428-435DOI: (10.1016/j.eururo.2015.06.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 4 Recurrence-free progression following radiation stratified by pre–radiation therapy biopsy grade (no hormone therapy cohort). Green line: Gleason score ≤6, grade group 1. Orange line: Gleason score 3+4, grade group 2. Dark blue line: Gleason score 4+3, grade group 3. Red line: Gleason score 8, grade group 4. Purple line: Gleason score ≥9, grade group 5. RFP=recurrence-free progression. European Urology 2016 69, 428-435DOI: (10.1016/j.eururo.2015.06.046) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 5 Images of cases diagnosed as Gleason score 6 prior to 2005 from Johns Hopkins Hospital, Henry Ford Hospital, University of California San Francisco, or Baylor College of Medicine (modified from Ross et al [17]). (A) Gleason pattern 4 with glomeruloid glands. (B) Gleason pattern 4 with medium-sized rounded cribriform gland. Associated small glands of pattern 3. (C) Gleason pattern 4 with poorly formed and fused glands. (D) Gleason pattern 4 with irregular cribriform gland with adjacent Gleason pattern 3. European Urology 2016 69, 428-435DOI: (10.1016/j.eururo.2015.06.046) Copyright © 2015 European Association of Urology Terms and Conditions